Eris Lifesciences gets SEBI’s approval to float IPO

12 May 2017 Evaluate

Pharmaceutical firm Eris Lifesciences has received markets regulator Securities and Exchange Board of India’s (SEBI) approval to raise funds through an initial public offering (IPO). The IPO comprises 28.87 million shares through an offer for sale by ChrysCap and promoters. The company’s shares are proposed to be listed on the BSE and NSE.

The company had filed draft prospectus with Sebi in February and the markets regulator has issued final observation on the IPO papers on April 28. Listing will provide a public market for the equity shares in India. The lead managers for the issue are Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).  

Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.

Eris Lifesciences Share Price

1389.70 -22.85 (-1.62%)
18-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.30
Dr. Reddys Lab 1275.05
Cipla 1472.05
Lupin 2098.70
Zydus Lifesciences 979.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.